Join
Live feed
·
PRReleasevia Quantisnow
Kalaris Therapeutics Inc. logo

Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
KLRS· Kalaris Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KLRS (Kalaris Therapeutics Inc.) and more on Quantisnow.